Genelux Corporation, a late clinical-stage immuno-oncology company based in Westlake Village, California, has disclosed the pricing details of its recent underwritten public offering. The offering consists of 6,666,667 shares of common stock being sold at a price of $3.00 per share to the public. Notably, all of the shares included in this offering will be sold by Genelux itself.